Growing Burden of Autoimmune Disorders, Expanding Biologic Pipeline, and Increasing Orphan Drug Support Accelerate Market Expansion.Austin, United States, March 19, 2026 (GLOBE NEWSWIRE) -- ...
The FDA has granted fast track designation to the anti-FcRn agent nipocalimab for the treatment of adults with systemic lupus erythematosus, according to a manufacturer press release. Nipocalimab ...
aDepartment of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital Heidelberg, Heidelberg 69120, Germany bDepartment of Rheumatology, University Hospital Düsseldorf, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results